Volume 16, Issue 8 (November 2022)                   Qom Univ Med Sci J 2022, 16(8): 654-663 | Back to browse issues page

Ethics code: IR.SSU.MEDICINE.REC.1399.170
Clinical trials code: IRCT20191106045356N3

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shomali Ahmadabad M, Zabihi M, Dastjerdi G, Movahedian Z, Heidari Khormizi S M, Ahmadi Mehrabad S R et al . Comparing the Effects of Methadone Administration with Sertraline or Venlafaxine on Depression, Anxiety, and Stress of Patients With Substance Abuse: A Clinical Trial. Qom Univ Med Sci J 2022; 16 (8) :654-663
URL: http://journal.muq.ac.ir/article-1-3459-en.html
Comparing the Effects of Methadone Administration with Sertraline or Venlafaxine on Depression, Anxiety, and Stress of Patients With Substance Abuse: A Clinical Trial
Mehdi Shomali Ahmadabad1 , Mohsen Zabihi * 2, Ghasem Dastjerdi3 , Zahra Movahedian4 , Seyed Moazeddin Heidari Khormizi5 , Seyed Reza Ahmadi Mehrabad5 , Atefeh Barkhordari Ahmadabadi6
1- Clinical Psychology Center, Department of Education, Ardakan, Yazd, Iran
2- Department of Pharmacology, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , mzabihi100@gmail.com
3- Shahid Sadoughi University of Medical Sciences
4- Clinical Psychology Center, Department of Education, Yazd, Iran.
5- Department of Pharmacology, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
6- Department of Clinical Psychology, Isfahan Branch (Khorasgan), Islamic Azad University, Isfahan, Iran.
Abstract:   (581 Views)
Background and Objectives: Psychological problems caused by drug addiction or cessation of drug use can increase the risk of relapse in patients under methadone maintenance treatment. This study aims to compare the effects of the administration of methadone with sertraline or venlafaxine on depression, anxiety, and stress of patients with substance abuse.
Methods: This is a clinical trial with a pre-test/post-test design. Participants were 40 patients under methadone therapy who were selected by voluntary sampling method and randomly divided into two groups. The first group received methadone plus venlafaxine and the second group received methadone plus sertraline. Patients were evaluated using the depression, anxiety, stress scale. Data were analyzed using paired t-test and analysis of covariance. The significance level was set at 0.05.
Results: Both sertraline and venlafaxine significantly affected depression, anxiety, and stress levels of patients (P<0.001). No significant difference was observed between the effects of sertraline and venlafaxine (P>0.05).
Conclusion: Venlafaxine and sertraline can be used to improve the mental health of patients under methadone therapy. Their selection can be based on the psychiatrist’s opinion and the amount of drug side effects.
Keywords: Venlafaxine, Sertraline, Mental Health, Methadone
Full-Text [PDF 3411 kb]   (232 Downloads) |   |   Full-Text (HTML)  (2486 Views)  
Type of Study: Original Article | Subject: pharmacology
Received: 2022/05/3 | Accepted: 2022/09/28 | Published: 2022/11/1
References
1. Azagba S, Shan L, Qeadan F, Wolfson M. Unemployment rate, opioids misuse and other substance abuse: Quasi-experimental evidence from treatment admissions data. BMC Psychiatry. 2021; 21(1):22. [DOI:10.1186/s12888-020-02981-7] [PMID] [PMCID] [DOI:10.1186/s12888-020-02981-7]
2. Javed S, Chughtai K, Kiani S. Substance abuse: From abstinence to relapse. Life Sci. 2020; 1(2):68-71. [DOI:10.37185/LnS.1.1.94] [DOI:10.37185/LnS.1.1.94]
3. Frank D. A chance to do it better: Methadone maintenance treatment in the age of Covid-19. J Subst Abuse Treat. 2021; 123:108246. [DOI:10.1016/j.jsat.2020.108246] [PMID] [PMCID] [DOI:10.1016/j.jsat.2020.108246]
4. Malla MA. Substance abuse and mental health disorder among the youth living in conflict environment. J Mental Health Issu Behav. 2021; 1(1):12-22. [Link] [DOI:10.55529/jmhib.11.12.22]
5. Matsumoto A, Santelices C, Lincoln AK. Perceived stigma, discrimination and mental health among women in publicly funded substance abuse treatment. Stigma Health. 2021; 6(2):151-62. [DOI:10.1037/sah0000226] [DOI:10.1037/sah0000226]
6. Windarwati HD, Megananda NK, Nova R, Kusumawati MW, Ati NAL. Stress, anxiety, and depression with potential adolescent drug abuse: a cross-sectional study. J Keperawatan. 2021; 13(1):191-202. [Link]
7. Giovannetti C, Garcia Arce S, Rush B, Mendive F. Pilot evaluation of a residential drug addiction treatment combining traditional amazonian medicine, ayahuasca and psychotherapy on depression and anxiety. J Psychoactive Drugs. 2020; 52(5):472-81. [DOI:10.1080/02791072.2020.1789247] [PMID] [DOI:10.1080/02791072.2020.1789247]
8. Wemm SE, Sinha R. Drug-induced stress responses and addiction risk and relapse. Neurobiol Stress. 2019; 10:100148. [DOI:10.1016/j.ynstr.2019.100148] [PMID] [PMCID] [DOI:10.1016/j.ynstr.2019.100148]
9. Rashid Z, Rashid M. [The Effectiveness of integrated meta-diagnostic therapy on specific symptoms of major depression, high risk behaviors, emotion regulation, and anxiety in methadone dependents (Persian)]. J Psychol New Ideas. 2021; 9(13):1-12. [Link]
10. Ommolbani R, Aghayousefi A, Oraki M. [Comparing the effects of combined cognitive behavioral therapy and methadone therapy with the association of narcotics anonymous addicts on executive functions of quitting drugs volunteer addicts in Jiroft (Persian)]. J Jiroft Uni Med Sci. 2020; 7(2):366-73. [Link]
11. Ge ZY, Yang LM, Xia JJ, Fu XH, Zhang YZ. Possible aerosol transmission of covid-19 and special precautions in dentistry. J Zhejiang Univ Sci B. 2020; 21(5):361-8. [DOI:10.1631/jzus.B2010010] [PMCID] [DOI:10.1631/jzus.B2010010]
12. Koo JR, Yoon JY, Joo MH, Lee HS, Oh JE, Kim SG, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005; 329(1):1-5. [DOI:10.1097/00000441-200501000-00001] [PMID] [DOI:10.1097/00000441-200501000-00001]
13. Lofgren SM, Velamakanni SS, Huppler Hullsiek K, Bangdiwala AS, Namudde A, Musubire AK, et al. The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. Wellcome Open Res. 2021; 6(45):45. [DOI:10.12688/wellcomeopenres.16363.1] [DOI:10.12688/wellcomeopenres.16363.1]
14. Kassis KN. Is sertraline effective at reducing the symptoms of anxiety in those diagnosed with generalized anxiety disorder (GAD)? [MSc. thesis]. Philadelphia: Philadelphia College of Osteopathic Medicine; 2020. [Link]
15. Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai WY, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol. 2019; 86(4):552-60. [DOI:10.1002/ana.25561] [PMID] [PMCID] [DOI:10.1002/ana.25561]
16. Rauch SA, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R, et al. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry. 2019; 76(2):117-26. [DOI:10.1001/jamapsychiatry.2018.3412] [PMID] [PMCID] [DOI:10.1001/jamapsychiatry.2018.3412]
17. Papp M, Gruca P, Lason M, Niemczyk M, Willner P. The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression. J Psychopharmacol. 2019 ;33(6):748-56. [DOI:10.1177/0269881119827889] [PMID] [DOI:10.1177/0269881119827889]
18. Tran TTT, Nguyen DM, Dao AQ, Le VT, Vasseghian Y. A state-of-the-art review on the nanomaterial-based sensor for detection of venlafaxine. Chemosphere. 2022; 297:134116. [DOI:10.1016/j.chemosphere.2022.134116] [PMID] [DOI:10.1016/j.chemosphere.2022.134116]
19. Du Y, Feng R, Zhang W, Fang J, Ma K, Wang E, et al. Single I.V.-ketamine augmentation of newly initiated venlafaxine hydrocortisone for treatment-resistant depression: Randomized, double-blind controlled study protocol. 2022. [Unpublished]. [DOI:10.21203/rs.3.rs-1244643/v1] [DOI:10.21203/rs.3.rs-1244643/v1]
20. Whiston A, Lennon A, Brown C, Looney C, Larkin E, O'Sullivan L, et al. A systematic review and individual patient data network analysis of the residual symptom structure following cognitive-behavioral therapy and escitalopram, mirtazapine and venlafaxine for depression. Front Psychiatry. 2022; 13:746678.[DOI:10.3389/fpsyt.2022.746678] [PMID] [PMCID] [DOI:10.3389/fpsyt.2022.746678]
21. Junli L, Mengru L, Jinyu L, Ling J, Lijun Z. Clinical analysis of topiramate titration combined with venlafaxine in the treatment of chronic migraine with generalized anxiety disorder. Chin Gen Pract. 2021; 24(2):243-47. [Link]
22. Sharbafchi MR, Afshar H, Adhamian P, Feizi A, Daghaghzadeh H, Adibi P. Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome. J Res Med Sci. 2020; 25:115. [PMID] [PMCID] [DOI:10.4103/jrms.JRMS_699_19]
23. Hosseini Kiasari ST, Ghamari Givi H, Khaleqkhah A. [The efficacy of cognitive-existential group therapy in reducing the levels of depression, anxiety and stress in patients with multiple sclerosis (Persian)]. J Mazandaran Uni Med Sci. 2015; 24(122):368-72. [Link]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Qom University of Medical Sciences Journal

Designed & Developed by : Yektaweb